Compare LARK & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | VTVT |
|---|---|---|
| Founded | 1885 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 143.7M |
| IPO Year | N/A | 2015 |
| Metric | LARK | VTVT |
|---|---|---|
| Price | $27.25 | $36.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.25 |
| AVG Volume (30 Days) | 5.8K | ★ 21.1K |
| Earning Date | 01-28-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 42.74 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | ★ $68,286,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.93 | ★ N/A |
| Revenue Growth | ★ 17.39 | N/A |
| 52 Week Low | $21.31 | $14.00 |
| 52 Week High | $29.56 | $44.00 |
| Indicator | LARK | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 50.19 |
| Support Level | $27.10 | $31.99 |
| Resistance Level | $28.99 | $37.98 |
| Average True Range (ATR) | 0.76 | 3.39 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 60.45 | 45.60 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.